Van ECK Associates Corp Sells 4,813,780 Shares of Pfizer Inc. $PFE

Van ECK Associates Corp trimmed its stake in Pfizer Inc. (NYSE:PFE) by 26.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,342,760 shares of the biopharmaceutical company’s stock after selling 4,813,780 shares during the quarter. Van ECK Associates Corp owned 0.23% of Pfizer worth $332,234,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Horizon Financial Services LLC boosted its holdings in Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. bought a new position in shares of Pfizer during the fourth quarter valued at $26,000. YANKCOM Partnership bought a new position in shares of Pfizer during the fourth quarter valued at $28,000. HFM Investment Advisors LLC lifted its holdings in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Darwin Wealth Management LLC bought a new position in shares of Pfizer during the second quarter valued at $32,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 0.1%

Pfizer stock opened at $26.19 on Friday. The stock has a market cap of $149.26 billion, a PE ratio of 19.99 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The stock has a fifty day moving average of $26.43 and a 200 day moving average of $26.32.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. The ex-dividend date was Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s new weight-loss data is being viewed as encouraging for its obesity franchise, potentially improving the competitive case for its pipeline and helping sentiment around future growth. Article Title
• Positive Sentiment: Pfizer’s expanded U.S. label for HYMPAVZI is adding to optimism around the hemophilia business by widening the addressable patient pool, which may support future specialty-drug sales. Article Title
• Positive Sentiment: RBC recently upgraded Pfizer to Sector Perform, saying the valuation has reset and the risk-reward profile looks more balanced ahead of pipeline catalysts. Article Title
• Positive Sentiment: Some recent articles argue Pfizer’s Seagen oncology platform and newly acquired obesity assets could help offset patent-expiry and post-COVID revenue pressure, supporting a long-term turnaround thesis. Article Title
• Neutral Sentiment: Analysts currently rate Pfizer around Hold on average, suggesting the market sees limited near-term upside until more pipeline and commercial execution proves out. Article Title
• Negative Sentiment: Bearish commentary continues to highlight Pfizer’s dividend yield as a sign of underlying concern about cash flow, debt, and the company’s ability to support both payouts and reinvestment. Article Title

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a report on Monday, March 2nd. Bank of America lowered their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. CICC Research initiated coverage on Pfizer in a report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. UBS Group reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.82.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.